Clinical-stage immunotherapy development in oncology and infectious disease.
Independent editorial and sponsored coverage are visibly separated. Sponsored company reports carry a clear commercial-relationship disclosure and remain subject to the same sourcing, byline, date and correction standards as other newsroom reports.
BioVaxys Technology Corp. reported positive findings from a Phase 2 clinical study evaluating maveropepimut-S (MVP-S) with pembrolizumab and low-dose cyclophosphamide in patients with advanced or metastatic bladder cancer.
Read full report →BioVaxys reported positive preliminary results from the investigator-initiated Phase 1B/2 PESCO study in recurrent epithelial ovarian cancer.
Read full report →Send verifiable public material, a factual correction or a news tip to the editorial desk. Submissions are reviewed independently and do not guarantee publication.
